Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
Active, not recruiting · NCT03851614 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, myomatous neoplasm, neoplasm, pancreatic adenocarcinoma, sarcoma | Active, not recruiting | Phase 2 | 2026-10-05 | NCT03851614 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| University Health Network, Toronto | 417 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Princess Margaret Cancer Centre | Toronto | Canada | 145 |